[go: up one dir, main page]

MXPA05008541A - Formulaciones de almacenamiento estable y bioestables de inhibidores ace y metodos para su preparacion. - Google Patents

Formulaciones de almacenamiento estable y bioestables de inhibidores ace y metodos para su preparacion.

Info

Publication number
MXPA05008541A
MXPA05008541A MXPA05008541A MXPA05008541A MXPA05008541A MX PA05008541 A MXPA05008541 A MX PA05008541A MX PA05008541 A MXPA05008541 A MX PA05008541A MX PA05008541 A MXPA05008541 A MX PA05008541A MX PA05008541 A MXPA05008541 A MX PA05008541A
Authority
MX
Mexico
Prior art keywords
stable
bio
storage
ace inhibitors
formulations
Prior art date
Application number
MXPA05008541A
Other languages
English (en)
Inventor
Spireas Spiridon
Original Assignee
Sigmapharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32871609&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA05008541(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US10/364,970 external-priority patent/US20030225124A1/en
Application filed by Sigmapharm Inc filed Critical Sigmapharm Inc
Publication of MXPA05008541A publication Critical patent/MXPA05008541A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invencion proporciona formulaciones estables en almacenamiento y bioestables de inhibidores ACE, especialmente maleato de enalapril e hidrocloruro de quinapril, que pueden fabricarse en una manera de tiempo eficiente y de costo efectivo. Tales formulaciones pueden prepararse de manera simple y sobre una gran escala industrial utilizando metodos y equipo convencionales. La presente invencion tambien proporciona metodos para la preparacion de formulaciones altamente fabricables, estables en almacenamiento y bioestables de inhibidores ACE, especialmente maleato de enalapril e hidrocloruro de quinapril. Tambien se proporcionan metodos para el tratamiento de trastornos cardiovasculares que utilizan las formulaciones estables en almacenamiento y bioestables de inhibidores ACE, especialmente maleato de enalapril e hidrocloruro de quinapril.
MXPA05008541A 2003-02-12 2003-12-05 Formulaciones de almacenamiento estable y bioestables de inhibidores ace y metodos para su preparacion. MXPA05008541A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/364,970 US20030225124A1 (en) 1999-08-31 2003-02-12 Stable formulations of ACE inhibitors, and methods for preparation thereof
US10/727,805 US20040157911A1 (en) 1999-08-31 2003-12-04 Storage-stable and bio-stable formulations of ace inhibitors, and methods for preparation thereof
PCT/US2003/040132 WO2004071526A1 (en) 2003-02-12 2003-12-05 Storage-stable and bio-stable formulations of ace inhibitors, and methods for preparation thereof

Publications (1)

Publication Number Publication Date
MXPA05008541A true MXPA05008541A (es) 2005-11-17

Family

ID=32871609

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05008541A MXPA05008541A (es) 2003-02-12 2003-12-05 Formulaciones de almacenamiento estable y bioestables de inhibidores ace y metodos para su preparacion.

Country Status (6)

Country Link
US (1) US20040157911A1 (es)
EP (1) EP1594531B1 (es)
AU (1) AU2003297234B2 (es)
CA (1) CA2515745C (es)
MX (1) MXPA05008541A (es)
WO (1) WO2004071526A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080234353A1 (en) * 2004-03-24 2008-09-25 Reynir Eyjolfsson Formulations of Ramipril
GB0518129D0 (en) * 2005-09-06 2005-10-12 Arrow Int Ltd Ramipril formulation
GB2431579A (en) * 2005-10-28 2007-05-02 Arrow Int Ltd Ramipril formulations
US20070098782A1 (en) * 2005-10-28 2007-05-03 Selamine Limited Ramipril Formulation
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
GB0624090D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amine salts
NZ599783A (en) 2009-11-03 2013-10-25 Grifols Therapeutics Inc Composition and use for alpha-1 proteinase inhibitor
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
ES2648249T3 (es) 2009-11-24 2017-12-29 Grifols Therapeutics Inc. Procedimientos, composiciones y kits de liofilización

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US488668A (en) * 1892-12-27 Potato-masher
US568627A (en) * 1896-09-29 Carl j
JPS6248696A (ja) * 1985-08-27 1987-03-03 Kanegafuchi Chem Ind Co Ltd Ｎ−〔１（ｓ）−エトキシカルボニル−３−フエニルプロピル〕−ｌ−アラニル−ｌ−プロリンの製造法
US4830853A (en) * 1986-10-20 1989-05-16 Warner-Lambert Company Drug compositions stabilized against oxidation
US4793998A (en) * 1986-10-20 1988-12-27 Warner-Lambert Company Stabilized drug compositions
US4743450A (en) * 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
US4880631A (en) * 1987-09-24 1989-11-14 Merck & Co., Inc. Controlled porosity osmotic pump
DE3936053A1 (de) * 1989-10-28 1991-05-02 Basf Ag Verfahren zur verbesserung der bioverfuegbarkeit von pharmazeutischen wirkstoffen mit peptidbindungen
DE4123248C2 (de) * 1991-07-13 1996-03-07 Degussa Verfahren zur Herstellung von N-substituierten alpha-Aminosäuren und alpha-Aminosäure-Derivaten
YU48602B (sh) * 1991-11-25 1998-12-23 Krka Tovarna Zdravil P.O. Postupak za dobijanje stabilne formulacije soli enalaprila
US5350584A (en) * 1992-06-26 1994-09-27 Merck & Co., Inc. Spheronization process using charged resins
US20050090553A1 (en) * 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
ATE140621T1 (de) * 1993-04-15 1996-08-15 Gergely Gerhard Brausesystem mit einem alkali- und/oder metallempfindlichen, pharmazeutischen wirkstoff, und verfahren zur herstellung
AU2942495A (en) * 1994-07-13 1996-02-16 Lek Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Process for the preparation of compounds having ace inhibitory action as well as novel compounds useful as starting materials or intermediates in said process
CA2128199C (en) * 1994-07-15 1997-02-04 Bernard Charles Sherman Stable solid pharmaceutical compositions containing enalapril maleate
US5573780A (en) * 1995-08-04 1996-11-12 Apotex Usa Inc. Stable solid formulation of enalapril salt and process for preparation thereof
CA2182258C (en) * 1996-07-29 2001-04-17 K.S. Keshava Murthy Sodium enalapril complex and the use thereof to make sodium enalapril
US6153223A (en) * 1998-06-05 2000-11-28 Watson Pharmaceuticals, Inc. Stabilized pharmaceutical compositions
US6555551B1 (en) * 1999-08-31 2003-04-29 Mutual Pharmaceutical Co., Inc. Stable formulations of ACE inhibitors, and methods for preparation thereof
GB0020691D0 (en) * 2000-08-22 2000-10-11 Boehringer Ingelheim Pharma Pharmaceutical combination

Also Published As

Publication number Publication date
CA2515745A1 (en) 2004-08-26
AU2003297234B2 (en) 2007-12-13
AU2003297234A1 (en) 2004-09-06
CA2515745C (en) 2012-12-04
US20040157911A1 (en) 2004-08-12
EP1594531A1 (en) 2005-11-16
WO2004071526A1 (en) 2004-08-26
EP1594531A4 (en) 2008-04-09
EP1594531B1 (en) 2012-04-18

Similar Documents

Publication Publication Date Title
WO2006045119A3 (en) Improved inhibitors for the soluble epoxide hydrolase
WO2004078116A3 (en) P38 inhibitors and methods of use thereof
TW200510416A (en) P38 inhibitors and methods of use thereof
WO2004006858A3 (en) Compounds, compositions, and methods employing same
TW200507830A (en) Bronchodilating β -agonist compositions and methods
IL162838A0 (en) Compositions and methods for prevention and treatment peptide-of amyloid- related disorders
TW200514784A (en) Sulfonamide substituted imidazoquinolines
PT1509232E (pt) Uma combinação de um antagonista de nmda e inibidores da acetilcolina esterase para o tratamento da doença de alzheimer
WO2004089296A3 (en) Improved inhibitors for the soluble epoxide hydrolase
MY134480A (en) 4-pyrrolidino-phenyl-benzyl ether derivatives
DK1539166T3 (da) Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme
ATE409065T1 (de) Inhibitoren der 17 beta- hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten
EP1476471A4 (en) FUNCTIONAL FOODS FOR THE TREATMENT, PROTECTION AND RESTORATION OF CONNECTIVE TISSUES
MXPA05008541A (es) Formulaciones de almacenamiento estable y bioestables de inhibidores ace y metodos para su preparacion.
WO2005007117A3 (en) Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
WO2006074265A3 (en) Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
EP1831266A4 (en) RETICULATED AMINE POLYMERS
MY134019A (en) Aryl oxime-piperazines useful as ccr5 antagonists
WO2004098599A3 (en) Proton pump inhibitors for the treatment of lower abdominal disorders
IL155111A0 (en) Pharmaceutical compositions for inhibiting metal ion dependent enzymatic activity and methods for the use thereof
WO2006037032A3 (en) Prodrugs of protein tyrosine kinase inhibitors
WO2004078180A3 (en) Naaladase inhibitors for treating opioid tolerance
MY128529A (en) Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
EP1551452A4 (en) COMPOSITIONS AND METHODS FOR THERAPEUTIC TREATMENT
ZA200502464B (en) Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome.

Legal Events

Date Code Title Description
FG Grant or registration